Literature DB >> 29770921

Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.

Maria Rosaria Domenici1, Valentina Chiodi2, Mirko Averna2, Monica Armida2, Antonella Pèzzola2, Rita Pepponi2, Antonella Ferrante2, Michael Bader3, Kjell Fuxe4, Patrizia Popoli2.   

Abstract

The A2A adenosine receptor (A2AR) is widely distributed on different cellular types in the brain, where it exerts a broad spectrum of pathophysiological functions, and for which a role in different neurodegenerative diseases has been hypothesized or demonstrated. To investigate the role of neuronal A2ARs in neurodegeneration, we evaluated in vitro and in vivo the effect of the neurotoxin 3-nitropropionic acid (3-NP) in a transgenic rat strain overexpressing A2ARs under the control of the neural-specific enolase promoter (NSEA2A rats). We recorded extracellular field potentials (FP) in corticostriatal slice and found that the synaptotoxic effect of 3-NP was significantly reduced in NSEA2A rats compared with wild-type animals (WT). In addition, after exposing corticostriatal slices to 3-NP 10 mM for 2 h, we found that striatal cell viability was significantly higher in NSEA2A rats compared to control rats. These in vitro results were confirmed by in vivo experiments: daily treatment of female rats with 3-NP 10 mg/kg for 8 days induced a selective bilateral lesion in the striatum, which was significantly reduced in NSEA2A compared to WT rats. These results demonstrate that the overexpression of the A2AR selectively at the neuronal level reduced 3-NP-induced neurodegeneration, and suggest an important function of the neuronal A2AR in the modulation of neurodegeneration.

Entities:  

Keywords:  3-Nitropropionic acid; Adenosine A2A receptors; Huntington’s disease; Striatum; Synaptic transmission

Mesh:

Substances:

Year:  2018        PMID: 29770921      PMCID: PMC6107463          DOI: 10.1007/s11302-018-9609-4

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  61 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 2.  3-Nitropropionic acid animal model and Huntington's disease.

Authors:  C V Borlongan; T K Koutouzis; P R Sanberg
Journal:  Neurosci Biobehav Rev       Date:  1997-05       Impact factor: 8.989

3.  Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease.

Authors:  Jitendriya Mishra; Anil Kumar
Journal:  Pharmacol Rep       Date:  2014-08-01       Impact factor: 3.024

Review 4.  Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease.

Authors:  Patrizia Popoli; David Blum; Alberto Martire; Catherine Ledent; Stefania Ceruti; Maria P Abbracchio
Journal:  Prog Neurobiol       Date:  2007-01-09       Impact factor: 11.685

5.  Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.

Authors:  Alberto Martire; Gemma Calamandrei; Fabio Felici; Maria Luisa Scattoni; Giusi Lastoria; Maria Rosaria Domenici; Maria Teresa Tebano; Patrizia Popoli
Journal:  Neurosci Lett       Date:  2007-02-14       Impact factor: 3.046

6.  Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation.

Authors:  Qing-Yuan Huang; Catherine Wei; Liqun Yu; Joana E Coelho; Hai-Ying Shen; Anti Kalda; Joel Linden; Jiang-Fan Chen
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

7.  Transient inhibition of glutamate uptake in vivo induces neurodegeneration when energy metabolism is impaired.

Authors:  M R Sánchez-Carbente; L Massieu
Journal:  J Neurochem       Date:  1999-01       Impact factor: 5.372

8.  The stimulation of adenosine A2A receptors ameliorates the pathological phenotype of fibroblasts from Niemann-Pick type C patients.

Authors:  Sergio Visentin; Chiara De Nuccio; Antonietta Bernardo; Rita Pepponi; Antonella Ferrante; Luisa Minghetti; Patrizia Popoli
Journal:  J Neurosci       Date:  2013-09-25       Impact factor: 6.167

9.  Adenosine A2A receptor activation is determinant for BDNF actions upon GABA and glutamate release from rat hippocampal synaptosomes.

Authors:  Sandra Henriques Vaz; Sofia Rapaz Lérias; Sara Parreira; Maria José Diógenes; Ana Maria Sebastião
Journal:  Purinergic Signal       Date:  2015-10-09       Impact factor: 3.765

10.  Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.

Authors:  Savina Apolloni; Susanna Amadio; Chiara Parisi; Alessandra Matteucci; Rosa L Potenza; Monica Armida; Patrizia Popoli; Nadia D'Ambrosi; Cinzia Volonté
Journal:  Dis Model Mech       Date:  2014-07-18       Impact factor: 5.758

View more
  4 in total

1.  Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.

Authors:  Xiong Yang; Shi-Feng Chu; Zhen-Zhen Wang; Fang-Fang Li; Yu-He Yuan; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

Review 2.  Olfactory Dysfunction in Huntington's Disease.

Authors:  Jorge Patino; Nicholas E Karagas; Shivika Chandra; Nivedita Thakur; Erin Furr Stimming
Journal:  J Huntingtons Dis       Date:  2021

3.  Antioxidant and Antiinflammatory Effects of Epilobium parviflorum, Melilotus officinalis and Cardiospermum halicacabum Plant Extracts in Macrophage and Microglial Cells.

Authors:  Stefania Merighi; Alessia Travagli; Paola Tedeschi; Nicola Marchetti; Stefania Gessi
Journal:  Cells       Date:  2021-10-08       Impact factor: 6.600

Review 4.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.